A5028453073- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Sphingolipid Metabolism and Signaling
- Cancer Genomics and Diagnostics
- Caveolin-1 and cellular processes
- Immune cells in cancer
- TGF-β signaling in diseases
- CAR-T cell therapy research
- Virus-based gene therapy research
- interferon and immune responses
- Kruppel-like factors research
- Glioma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Cancer, Hypoxia, and Metabolism
- Genetic factors in colorectal cancer
- Neuroendocrine Tumor Research Advances
- Hippo pathway signaling and YAP/TAZ
- Cancer-related gene regulation
- Melanoma and MAPK Pathways
- Cell death mechanisms and regulation
- Fibroblast Growth Factor Research
- Hydrogels: synthesis, properties, applications
- Cellular Mechanics and Interactions
University of Verona
2020-2024
Abstract The TGFβ receptor inhibitor galunisertib demonstrated efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) the randomized phase II H9H-MC-JBAJ study, which compared plus chemotherapeutic agent gemcitabine alone. However, additional stromal paracrine signals might confer adaptive resistance that limits of this therapeutic strategy. Here, we found autotaxin, a secreted enzyme promotes inflammation and fibrosis by generating lysophosphatidic acid (LPA), mediates to...
Pancreatic cancer is one of the most lethal solid tumors, mainly because its intrinsic chemoresistance. We identified TAK1 as a central hub sustaining this resistance. Nanoliposomal irinotecan (nal-IRI) novel treatment for metastatic gemcitabine-refractory pancreatic cancer. endeavored to identify circulating markers activation predicting chemoresistance in setting.In vivo activity nal-IRI was validated an orthotopic nude murine model expressing TAK1-specific shRNA. Plasma concentration 20...
The development of efficient and biocompatible contrast agents is particularly urgent for modern clinical surgery. Nanostructured materials raised great interest as different imaging techniques, which essential features are high contrasts, in the case precise surgery, minimization signal spatial dispersion when embedded biological tissues. This study deals with a multimodal agent based on an injectable hydrogel nanocomposite containing lanthanide-activated layered double hydroxide coupled to...
Despite recent advances in the development of BRAF kinase inhibitors (BRAFi) for BRAF-mutant melanomas, resistance remains a major clinical problem. In addition to genetic alterations associated with intrinsic resistance, several adaptive response mechanisms are known be rapidly activated allow cell survival treatment, limiting efficacy. A better understanding driving is urgently needed improve success BRAF-targeted therapies and make therapeutic intervention more durable. this study, we...
<p>Figures S1-5, Tables S1-3</p>
<p>Figures S1-5, Tables S1-3</p>
<div>Abstract<p>The TGFβ receptor inhibitor galunisertib demonstrated efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) the randomized phase II H9H-MC-JBAJ study, which compared plus chemotherapeutic agent gemcitabine alone. However, additional stromal paracrine signals might confer adaptive resistance that limits of this therapeutic strategy. Here, we found autotaxin, a secreted enzyme promotes inflammation and fibrosis by generating lysophosphatidic acid (LPA),...
<div>Abstract<p>The TGFβ receptor inhibitor galunisertib demonstrated efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) the randomized phase II H9H-MC-JBAJ study, which compared plus chemotherapeutic agent gemcitabine alone. However, additional stromal paracrine signals might confer adaptive resistance that limits of this therapeutic strategy. Here, we found autotaxin, a secreted enzyme promotes inflammation and fibrosis by generating lysophosphatidic acid (LPA),...
Abstract The TGFβ receptor inhibitor galunisertib (GAL) exhibited promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) the randomized phase 2 H9H-MC-JBAJ study. However, identification of predictive biomarkers remains unique importance. We used a 279 multi-analyte panel and confirmed CCL3 as most significant plasma protein for chemoresistance receiving gemcitabine (GEM) [overall survival (mOS) (95%CI), high vs low, 3.6 (2.5-4.0) 10.1 (7.2-17.0) months, HR (95%CI)= 3.92...
Trastuzumab plus chemotherapy is the standard of care for first-line treatment patients with HER2+ advanced esophagogastric (EG) cancer. Nevertheless, frequently develop resistance. In preclinical models, we identified overexpression Fibroblast Growth Factor Receptor (FGFR) 3 as a mechanism potentially involved in trastuzumab-acquired FGFR inhibition could be potential second-line treatment. this Simon's two-stage phase 2, single arm study, EG cancer refractory to trastuzumab-containing...
<p>The hazard ratios (HRs) with 95% CI are shown in dependence of possible cutoff points IL-8 for median progression-free survival (mPFS) (A) and overall (mOS) (D) durations patients the discovery cohort. The differences mean times estimated each value mPFS (B) mOS (E). histogram shows relative frequency (C) (F). optimal is marked by a vertical line.</p>
<p>Kaplan-Meier curves of progression-free survival stratifying patients in the discovery cohort for a significant cut-off value eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).</p>
<p>HRs for progression-free survival duration of patients in the discovery cohort different values each cytokine evaluated: eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).</p>
<p>Kaplan-Meier curves of progression-free survival (A) and overall (B) in the discovery cohort population.</p>
<p>Kaplan-Meier curves of survival outcomes. Progression-free (A) and overall (B) in the validation cohort population.</p>
<p>The differences in mean progression-free survival duration of patients the discovery cohort are estimated for each value eotaxin (A), GM-CSF (B), Gro alpha(C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1 alpha (O), (P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).</p>
<p>Immunohistochemical analysis. Serial paraffin sections from tumors excised mice orthotopically inoculated with AsPC1 pancreatic cancer cells transduced lentiviruses expressing shTAK1 (AsPC1shTAK1) or a scramble sequence as control (AsPC1ctrl) were stained antibodies to CD68 carboxylesterase-2 (CES2). We measured similarly minimal levels (less than 1 cell/field) of CD68+ morphological features tumor associated macrophages (TAM) and in specimens bearing AsPc1 if compared that tumors</p>
<p>The histograms report the relative frequency for each cytokine value and distribution of values compared to cut-off calculated progression-free survival patients in discovery cohort. The are referred eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) TNF-alpha (S).</p>
<p>The histograms report the relative frequency for each cytokine value and distribution of values compared to cut-off calculated overall survival patients in discovery cohort. The are referred eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) TNF-alpha (S).</p>